Recurrence-associated genes in papillary thyroid cancer: An analysis of data from The Cancer Genome Atlas

Chien, Ming Nan; Yang, Po Sheng; Lee, Jie Jen; Wang, Tao Yeuan; Hsu, Yi Chiung; Cheng, Shih‐Ping

doi:10.1016/j.surg.2016.12.039

Cited by 32 publications

(39 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although TERT promoter mutation seems to be a promising prognostic factor in PTC, it is not the sole determinant of patient outcomes. Only 172 (19%) of 888 upregulated genes and 216 (27%) of 799 downregulated genes overlap with our previously identified recurrence‐associated genes . This is in keeping with the experience of others that adding the information of TERT promoter mutations had a modest improvement in predicting structural recurrence and cancer‐specific survival .…”

Section: Discussionsupporting

confidence: 86%

“…Metastases, patient age, completeness of resection, local invasion, and tumor size (MACIS) scores, American Thyroid Association (ATA) risk of recurrence, and tumor class (BRAF‐like vs RAS‐like) were referenced from the initial TCGA global analysis . The information on patient survival and disease recurrence was updated to the latest follow‐up . Statistical comparisons of clinicopathological parameters between groups were made using the chi‐square test, Fisher's exact test, or the Cochran‐Armitage trend test for categorical variables and unpaired 2‐tailed Student's t test for continuous variables.…”

Section: Methodsmentioning

confidence: 99%

“…The Cancer Genome Atlas (TCGA) provides multiplatform genomic data combined with patient‐matched clinical information, which has become a valuable tool to characterize the molecular landscape of cancer. Recently, we carried out a systemic search for recurrence‐associated genes using TCGA database and demonstrated that recurrence is associated with thyroid dedifferentiation . Thus far, the transcriptional signature in association with TERT promoter mutations has not been investigated.…”

Section: Introductionmentioning

confidence: 99%

“…Recently, we carried out a systemic search for recurrence-associated genes using TCGA database and demonstrated that recurrence is associated with thyroid dedifferentiation. 16 Thus far, the transcriptional signature in association with TERT promoter mutations has not been investigated. The purpose of this study was to analyze the TCGA expression profiles of papillary thyroid cancer (PTC) with or without TERT promoter mutations.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Transcriptome analysis of papillary thyroid cancer harboring telomerase reverse transcriptase promoter mutation

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Transcriptome analysis of papillary thyroid cancer harboring telomerase reverse transcriptase promoter mutation

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Overall, 32 genes belong to the list of genes in the Cancer Gene Census, including CCND1, FGFR1, PDGFRA, and TGFBR2. Moreover, 106 (12%) were among the recurrence‐associated genes that we previously reported . There were 158 genes upregulated in carcinomas and 697 genes downregulated in carcinomas.…”

Section: Resultsmentioning

confidence: 80%

Is papillary thyroid microcarcinoma a biologically different disease? A propensity score‐matched analysis

Hsu

Lee

Chien

et al. 2019

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background Papillary thyroid microcarcinoma exhibits an indolent clinical course and could be a candidate for active surveillance in the appropriate setting. It remains unknown whether papillary microcarcinoma is biologically different from larger papillary carcinoma >1 cm. Methods We analyzed clinicopathological information and transcriptome data of papillary thyroid cancer samples from The Cancer Genome Atlas. Propensity‐score matching was used to construct a matched cohort consisting of 29 microcarcinomas and 58 carcinomas. Principal component analysis and unsupervised hierarchical cluster analysis were carried out to investigate the similarity of gene expression profiles. Results After adjustment for differences in baseline clinicopathological and genetic factors, transcriptome could be grouped mainly on the basis of tumor class (BRAF‐like vs RAS‐like) and tumor size (microcarcinoma vs carcinoma). The gene set enrichment analysis showed that extracellular matrix‐associated pathways were enriched in the MSigDB database. Conclusion Papillary thyroid microcarcinomas display a distinct gene expression pattern different from the corresponding carcinomas. We hypothesize that tumor microenvironment may play a role in the microcarcinoma/carcinoma phenotypic divergence.

show abstract

Budding uninhibited by benzimidazoles 1 might be a poor prognosis biomarker promoting the progression of papillary thyroid cancer

Jiang

Bhandari

et al. 2023

Environmental Toxicology

View full text Add to dashboard Cite

BackgroundPapillary thyroid carcinoma (PTC) is one of the most widespread malignant tumors of the endocrine system, with a high incidence. Budding uninhibited by benzimidazoles 1 (BUB1), one of the spindle assembly checkpoint (SAC) genes, is a multitask protein kinase required for eukaryotic chromosome segregation. Although BUB1 has been explored in several types of cancer, its biological role and molecular mechanisms in PTC remain unclear.MethodsIn this study, we performed an examination of four public datasets along with local PTC cohorts and discovered that BUB1 was elevated in PTC compared to non‐cancer tissues. High BUB1 expression was linked with the status of BRAFV600E, RAS, and TERT after statistical analysis.ResultsClinically, BUB1 is associated with a variety of clinicopathological features in PTC patients. Interestingly, analysis of the TCGA database showed that BUB1 was closely associated with poor prognosis of PTC and significantly correlated with PFS. As determined by regression analysis, BUB1, and T stage were independent predictors of PTC and were related to BRAFV600E and lymph node metastatic status. By RT‐qPCR, BUB1 was considerably overexpressed in PTC cell lines in comparison with normal thyroid epithelial cells.ConclusionWe confirmed that the knockdown of BUB1 in BCPAP and TPC1 cell lines significantly inhibited cell proliferation, cloning, and migration in vitro experiments. These results imply that BUB1 may be a significant oncogenic gene that is directly associated with the prognosis of PTC and may represent a future target for therapeutic intervention.

show abstract

Recurrence-associated genes in papillary thyroid cancer: An analysis of data from The Cancer Genome Atlas

Cited by 32 publications

References 34 publications

Transcriptome analysis of papillary thyroid cancer harboring telomerase reverse transcriptase promoter mutation

Transcriptome analysis of papillary thyroid cancer harboring telomerase reverse transcriptase promoter mutation

Is papillary thyroid microcarcinoma a biologically different disease? A propensity score‐matched analysis

Budding uninhibited by benzimidazoles 1 might be a poor prognosis biomarker promoting the progression of papillary thyroid cancer

Contact Info

Product

Resources

About